OUR PEOPLE
Our People
Our People

Steven J. Abrams

Steven J. Abrams is a partner in the Corporate and Securities Practice Group and vice chair of the Life Sciences practice at Pepper Hamilton LLP, resident in the Philadelphia office. Mr. Abrams concentrates his practice in securities, venture capital, private equity, and merger and acquisition transactions. Mr. Abrams has experience in public and private offerings of equity and debt securities (representing issuers, underwriters and venture capital firms) and the acquisition and disposition of public and private companies. He also counsels senior management and boards of directors of companies on governance, disclosure and transactional matters. Mr. Abrams is a member of the firm’s Life Sciences Group and Sustainability, CleanTech and Climate Change Team.

Mr. Abrams has represented:
  • a clinical-stage biopharmaceutical company in its $40 million at-the-market equity program led by Cowen and Company
  • a clinical-stage biopharmaceutical company in its $50 million initial public offering of common stock through a syndicate of underwriters managed by Oppenheimer & Co., Guggenheim Securities and Needham & Company
  • a publicly traded clinical stage pharmaceutical company in a $65.5 million underwritten offering of common stock
  • the leading provider of consultative and analytically based promotional effectiveness solutions to the health care industry in a series of multi-million dollar acquisitions
  • a NASDAQ Global Market provider of integrated clinical documentation solutions for the U.S. health care system in its $130 million acquisition of a leader in advanced Speech and Natural Language Understanding technology
  • a NASDAQ Global Market provider of integrated promotional outsource services to life sciences companies in its $55 million acquisition of a privately held interactive digital communications agency serving biopharmaceutical companies
  • a publicly traded clinical stage pharmaceutical company in a $101.1 million underwritten offering of common stock
  • a publicly traded clinical-stage biopharmaceutical company in a registered direct public offering of common stock and warrants ($18.5 million)
  • a publicly traded clinical-stage pharmaceutical company in a follow-on public offering of common stock ($34 million)
  • a NASDAQ listed company in its delisting, dissolution and liquidation
  • a publicly traded clinical-stage pharmaceutical company in two registered direct public offerings of common stock ($45 million and $25 million)
  • a clinical-stage product-focused molecular imaging company in two rounds of financing ($28 million and $26 million) from major institutional investors
  • a publicly traded provider of clinical documentation workflow solutions in its multi-year project to become current in its filings with the Securities and Exchange Commission
  • a publicly traded clinical-stage pharmaceutical company in its $30 million venture loan financing
  • a promotion research company in its multi-million dollar acquisition of a pharmaceutical market research and consulting firm
  • a clean technology venture capital firm in its multi-million dollar investment in a leading developer and manufacturer of fully electric automotive vehicles
  • a clean technology venture capital firm in its multi-million dollar investment in a global leader in providing quality sensor instrumentation to the clean technology, medical and energy markets
  • a venture capital firm in its multi-million dollar investment in a commercial software company whose primary focus is addressing the growing need for effective automation and efficient regulatory compliance within pharmaceutical manufacturing
  • a NASDAQ Global Market biopharmaceutical company in its $43 million private placement of equity securities
  • a national provider of online insurance services in its multi-million dollar sale to a private equity financed purchaser
  • a national security integration company in its multi-million dollar merger with a publicly traded homeland security company
  • the management team of a leading manufacturer of automotive replacement parts in its $70 million sale to a private equity fund
  • a national retailer of custom sports apparel in its multi-million dollar venture financing
  • a publicly traded health care consulting and management services company in its sale to a private equity fund
  • a NASDAQ SmallCap Market company in its acquisition of the assets of a privately held service management software company
  • a NASDAQ National Market company’s $30 million add-on 144A high yield debt offering
  • a NASDAQ National Market company’s acquisition of the assets of a publicly traded medical technology company
  • a publicly traded biopharmaceutical company in its $30 million underwritten public offering of common stock through UBS Securities, JPMorgan and Jeffries & Company
  • a family in its $28 million sale of its interests in a national manufacturer and distributor of children’s clothing
  • an international manufacturer of diabetes insulin pumps in its $73 million initial public offering of common stock through a syndicate of underwriters managed by Piper Jaffray, JPMorgan and Thomas Weisel Partners
  • a publicly traded biopharmaceutical company in its $32 million registered direct offering of common stock through JPMorgan and UBS Securities
  • a publicly traded e-education technology solutions provider in its sale for $590 million to a U.S. public company
  • a registered financial holding company in its $37 million underwritten follow-on public offering of common stock managed by Legg Mason Wood Walker Incorporated
  • a private equity fund in the acquisition of the largest franchiser of in-home non-medical care in the United States
  • a Nasdaq solutions provider for the education, energy and utilities industries in its $17 million acquisition of a privately held solutions provider for the higher education market
  • a national specialty retailer of home decor in its $90 million underwritten initial public offering of common stock managed by Merrill Lynch & Co.
  • the largest optical franchisee system in the Southwest in a multi-million dollar sale of its franchise system
  • a NYSE technology infrastructure company in its $45 million acquisition of a privately held information technology consulting company
  • an e-commerce business-to-business industrial and construction supply company in a $52 million private equity financing
  • a publicly traded software company in its $11 million purchase of the assets of a competitor
  • a privately held Internet service provider in its sale for $10 million to a publicly traded competitor
  • Janney Montgomery Scott as underwriters’ counsel for a $19 million initial public offering of common stock for a manufacturer of test equipment for the semiconductor industry
  • a microbrewery in its $6.5 million underwritten initial public offering of common stock managed by A.S. Goldmen & Co.
  • Smith Barney Inc. as underwriters’ counsel for a $35 million initial public offering of common stock for a leading outbound teleservices company
  • J.P. Morgan Securities as underwriters’ counsel for a $160 million “roll up” initial public offering of common stock for a teleservices company
  • a leading provider of medical transcription services in its $35 million public offering of common stock through a syndicate of underwriters managed by Robertson, Stephens & Co.
  • a publicly traded computer reseller/distributor in its sale for $60 million to a Canadian competitor through a tender offer under the federal securities laws.
Mr. Abrams has lectured to various groups and published on securities and governance issues. He has presented seminars to the Institute of Internal Auditors and the Institute of Management Accountants concerning the Sarbanes-Oxley Act of 2002. Mr. Abrams’ article, “Non-Generally Accepted Accounting Principles and Reporting of Earnings Releases” was published as the lead article in the Spring 2003 issue of Trends and Developments in Corporate Governance – The Comparative Law Yearbook of International Business, published by The Center for International Legal Studies. Mr. Abrams is an Honorary Fellow of the Association of Fellows and Legal Scholars of the Center for International Legal Studies.

Education
B.A. 1990, summa cum laude, Rutgers College
J.D. 1995, cum laude, University of Pennsylvania Law School


Bar Admissions
Admitted to practice in New Jersey and Pennsylvania


Copyright © 2014 Pepper Hamilton LLP | Use of This Site Subject to These Terms & Conditions | PRIVACY POLICY | Contact Us: phinfo@pepperlaw.com or 866.737.7372 | Find Pepper Hamilton LLP on Facebook | Pepper Hamilton LLP on LinkedIn | Follow Pepper Hamilton LLP on Twitter | Pepper Hamilton LLP YouTube Channel | View Pepper Hamilton LLP's documents on JD Supra